[{"x_label":"High-grade glioma/astrocytoma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 122)","specimen_descriptor_fill":"Pediatric Primary Tumors","box_sample_count":89,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"PBTA","Disease":"High-grade glioma/astrocytoma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":12.77,"TPM_sd":8.68,"TPM_min":1.02,"TPM_25th_percentile":6.95,"TPM_median":9.79,"TPM_75th_percentile":15.18,"TPM_max":42.91},{"x_label":"High-grade glioma/astrocytoma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 122)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":33,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"PBTA","Disease":"High-grade glioma/astrocytoma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":7.66,"TPM_sd":3.39,"TPM_min":3.44,"TPM_25th_percentile":4.7,"TPM_median":7.12,"TPM_75th_percentile":10.45,"TPM_max":16.03},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":152,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.14,"TPM_sd":1.52,"TPM_min":0.85,"TPM_25th_percentile":3.01,"TPM_median":4.01,"TPM_75th_percentile":5.04,"TPM_max":9.03},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.94,"TPM_sd":2.97,"TPM_min":0.99,"TPM_25th_percentile":3.9,"TPM_median":4.34,"TPM_75th_percentile":4.9,"TPM_max":12.09},{"x_label":"Low-grade glioma/astrocytoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":507,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Low-grade glioma/astrocytoma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016685","MONDO":"MONDO_0016685","GTEx_tissue_subgroup_UBERON":"","TPM_mean":5.6,"TPM_sd":1.98,"TPM_min":1.79,"TPM_25th_percentile":4.16,"TPM_median":5.37,"TPM_75th_percentile":6.73,"TPM_max":13.23},{"x_label":"Low-grade glioma/astrocytoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Low-grade glioma/astrocytoma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016685","MONDO":"MONDO_0016685","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.86,"TPM_sd":1.93,"TPM_min":1.41,"TPM_25th_percentile":3.61,"TPM_median":4.63,"TPM_75th_percentile":6.29,"TPM_max":8.11},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":373,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.23,"TPM_sd":1.58,"TPM_min":1.1,"TPM_25th_percentile":3.18,"TPM_median":4.02,"TPM_75th_percentile":5,"TPM_max":11.23},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.23,"TPM_sd":1.72,"TPM_min":1.63,"TPM_25th_percentile":3.39,"TPM_median":4.89,"TPM_75th_percentile":5.41,"TPM_max":5.84},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Primary Tumors","box_sample_count":258,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.43,"TPM_sd":2.19,"TPM_min":1.08,"TPM_25th_percentile":2.92,"TPM_median":4.11,"TPM_75th_percentile":5.44,"TPM_max":19.22},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":3,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 1.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.45,"TPM_sd":1.65,"TPM_min":2.79,"TPM_25th_percentile":3.63,"TPM_median":4.48,"TPM_75th_percentile":5.28,"TPM_max":6.08}]